Blog

Achaogen Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $22.50 per share, […]

By |May 25th, 2017|Lifescinews|Comments Off on Achaogen Announces Pricing of Public Offering of Common Stock

LifeSci Advisors — Daily Market Digest — Thursday, May 25, 2017

BioShares Biotechnology Clinical Trials (BBC): $22.29, +$0.07, +21.1% YTD BioShares Biotechnology Products (BBP): $36.80, +$0.47, +12.4% YTD     MARKET COMMENTARY   Wall Street was set for a higher start, mirroring gains in global markets, after the U.S. Federal Reserve signaled caution in raising […]

By |May 25th, 2017|Daily Digest|Comments Off on LifeSci Advisors — Daily Market Digest — Thursday, May 25, 2017

LifeSci Advisors — Daily Market Digest — Wednesday, May 24, 2017

BioShares Biotechnology Clinical Trials (BBC): $22.22, +$0.12, +20.7% YTD BioShares Biotechnology Products (BBP): $36.33, -$0.14, +10.9% YTD     MARKET COMMENTARY   U.S. stock index futures were little changed as investors remained on the sidelines ahead of minutes of the Federal Reserve’s […]

By |May 24th, 2017|Daily Digest|Comments Off on LifeSci Advisors — Daily Market Digest — Wednesday, May 24, 2017

BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a presentation as part of a panel on biotechnology at the Mauldin Economics’ Strategic Investment Conference on Wednesday, May 24 at 3:20pm EDT at the Omni Orlando […]

By |May 24th, 2017|Lifescinews|Comments Off on BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24

Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product

Lysogene (LYS.PA) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered into a strategic manufacturing agreement with Brammer Bio, a best-in-class viral gene and cell therapy manufacturer.

By |May 24th, 2017|Lifescinews|Comments Off on Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product

Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference

NESS ZIONA, Israel, May 24, 2017 (GLOBE NEWSWIRE) — Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that a poster comprising updated data from the Company’s U.S. Phase 2 clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) […]

By |May 24th, 2017|Lifescinews|Comments Off on Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference

Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017

BOSTON, May 24, 2017 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented at ASM Microbe 2017, to be held June 1 – 5 in New Orleans. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based […]

By |May 24th, 2017|Lifescinews|Comments Off on Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017

Sierra Oncology to Present Innovative Clinical Trial Enhancements Leveraging Chk1 Synthetic Lethality in Two Posters at ASCO Annual Meeting

VANCOUVER , May 24, 2017 /CNW/ – Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that it will be presenting two Trials in Progress posters describing the innovative Phase 1 clinical designs for […]

By |May 24th, 2017|Lifescinews|Comments Off on Sierra Oncology to Present Innovative Clinical Trial Enhancements Leveraging Chk1 Synthetic Lethality in Two Posters at ASCO Annual Meeting

TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer

SAN DIEGO, May 24, 2017 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration (AMD) and fibrotic diseases, announced today that the first patient has been dosed in a Phase 1/2 clinical trial of TRC253 in […]

By |May 24th, 2017|Lifescinews|Comments Off on TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer

Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

GENEVA & NANTES, France–(BUSINESS WIRE) — Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™. The agreement builds upon previous collaboration between the two companies as announced […]

By |May 23rd, 2017|Lifescinews|Comments Off on Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

PARIS, May 23, 2017 (GLOBE NEWSWIRE) — Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the company has received the 10th unanimous recommendation from the Data Safety Monitoring Board (DSMB), to continue […]

By |May 23rd, 2017|Lifescinews|Comments Off on Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

Albireo Announces Proposed Public Offering of Common Stock

BOSTON, May 23, 2017 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced an underwritten public offering of its common stock. In connection with the offering, Albireo intends to grant the underwriters a 30-day option to purchase up […]

By |May 23rd, 2017|Lifescinews|Comments Off on Albireo Announces Proposed Public Offering of Common Stock

Achaogen Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of up to 5,000,000 shares of its common stock. All of the shares to be sold […]

By |May 23rd, 2017|Lifescinews|Comments Off on Achaogen Announces Proposed Public Offering of Common Stock

Plazomicin Granted FDA Breakthrough Therapy Designation

May 23, 2017

SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for plazomicin, Achaogen’s lead product candidate being developed for the treatment of […]

By |May 23rd, 2017|Lifescinews|Comments Off on Plazomicin Granted FDA Breakthrough Therapy Designation

LifeSci Advisors — Daily Market Digest — Tuesday, May 23, 2017

BioShares Biotechnology Clinical Trials (BBC): $22.10, -$0.10, +20.0% YTD BioShares Biotechnology Products (BBP): $36.47, -$0.27, +11.4% YTD     MARKET COMMENTARY   U.S. stock index futures were modestly higher ahead of economic data and President Donald Trump’s first full budget plan. Markit’s […]

By |May 23rd, 2017|Daily Digest|Comments Off on LifeSci Advisors — Daily Market Digest — Tuesday, May 23, 2017

OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists

NANTES, France, May 22, 2017 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA (ISIN:FR0012127173); (Mnémo:OSE) announced today the appointment of Aurore Morello, Ph.D., as Immunology Researcher, and Riad Abès, Ph.D., as CMC Project Manager, further strengthening the Company’s R&D team, based in Nantes.

By |May 23rd, 2017|Lifescinews|Comments Off on OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists

Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference

WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in […]

By |May 23rd, 2017|Lifescinews|Comments Off on Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference

Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial

WARRINGTON, Pa., May 22, 2017 /PRNewswire/ — Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has been awarded $0.9 million under a previously announced Phase II Small Business Innovation Research Grant (SBIR) valued at up to $2.6 million from the National […]

By |May 23rd, 2017|Lifescinews|Comments Off on Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial

Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system

Copenhagen, May 23, 2017 – Zealand Pharma (“Zealand”) announces positive results from a Phase 2a trial following administration of the multiple-dose version of dasiglucagon in adult patients with type 1 diabetes. Dasiglucagon is a glucagon analogue fully owned by Zealand with a unique stability profile in liquid formulation and a potential first-in-class glucagon analogue suitable […]

By |May 23rd, 2017|Lifescinews|Comments Off on Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system

BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)

ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that BioTime, and its subsidiary Cell Cure Neurosciences Ltd., will be featured in two presentations at the 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED) on Wednesday, May 24, 2017 […]

By |May 23rd, 2017|Lifescinews|Comments Off on BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

AUSTIN, Texas, May 23, 2017 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided an AEB1102 program and corporate update. AEB1102, the company’s lead investigational molecule, is an engineered human enzyme designed […]

By |May 23rd, 2017|Lifescinews|Comments Off on Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

INNATE PHARMA : IPH4102: Completion of the dose escalation part of the phase I trial – Data to be presented at ICML in June 2017 in Lugano

Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today announced that it has completed the dose escalation part of its ongoing Phase I trial evaluating IPH4102 in patients with relapsed/refractory cutaneous T cell lymphomas. No dose-limiting toxicity was reported and the maximum tolerated dose (MTD) was not reached.

By |May 22nd, 2017|Lifescinews|Comments Off on INNATE PHARMA : IPH4102: Completion of the dose escalation part of the phase I trial – Data to be presented at ICML in June 2017 in Lugano

Kiadis to Host Key Opinion Leader Meeting on Addressing the Risks of Haloidentical HSCT in Blood Cancer

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announced it will host a Key Opinion Leader meeting on the topic of […]

By |May 22nd, 2017|Lifescinews|Comments Off on Kiadis to Host Key Opinion Leader Meeting on Addressing the Risks of Haloidentical HSCT in Blood Cancer

BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC

HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 22, 2017 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the Company will present data from its Phase 2 clinical study of NurOwn® in amyotrophic lateral sclerosis (ALS) at the Inaugural “Cell & Gene Exchange” conference […]

By |May 22nd, 2017|Lifescinews|Comments Off on BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC

iCAD to Participate in Two Upcoming Investor Conferences

NASHUA, N.H., May 22, 2017 (GLOBE NEWSWIRE) — iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that management will be participating in the 14th Annual Craig-Hallum Institutional Investor Conference, as well as presenting at the 7th Annual […]

By |May 22nd, 2017|Lifescinews|Comments Off on iCAD to Participate in Two Upcoming Investor Conferences

Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry

EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) — Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that new data on the mechanism of action of ZX008 was presented in a poster at the 72nd Annual Meeting of the Society of Biological […]

By |May 22nd, 2017|Lifescinews|Comments Off on Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry

Rockwell Medical Issues Letter to Shareholders Explaining Why Electing Mark Ravich Could Do Lasting Harm

WIXOM, Mich., May 22, 2017 (GLOBE NEWSWIRE) — Rockwell Medical, Inc. (RMTI) today mailed a letter to its shareholders in connection with the Company’s upcoming 2017 Annual Meeting of Shareholders (“Annual Meeting”) to be held on June 1, 2017.

By |May 22nd, 2017|Lifescinews|Comments Off on Rockwell Medical Issues Letter to Shareholders Explaining Why Electing Mark Ravich Could Do Lasting Harm

Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association

NEWTOWN, Pa., May 22, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced multiple presentations discussing clinical and non-clinical studies relating to their oral rigosertib plus azacitidine combination therapy for […]

By |May 22nd, 2017|Lifescinews|Comments Off on Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association

LifeSci Advisors — Daily Market Digest — Monday, May 22, 2017

BioShares Biotechnology Clinical Trials (BBC): $22.20, +$0.05, +20.6% YTD BioShares Biotechnology Products (BBP): $36.74, -$0.31, +12.2% YTD     MARKET COMMENTARY   U.S. stock index futures were little changed as a rise in oil prices offset concerns regarding ongoing political turmoil in […]

By |May 22nd, 2017|Daily Digest|Comments Off on LifeSci Advisors — Daily Market Digest — Monday, May 22, 2017

Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine

SAN DIEGO–(BUSINESS WIRE) — La Jolla Pharmaceutical Company (LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) have been published online by The New England Journal of Medicine (NEJM). The article, entitled “Angiotensin II for the Treatment of […]

By |May 21st, 2017|Lifescinews|Comments Off on Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine